Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity
Benzinga Newsdesk 2 days ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Encouraging tolerability profile with stomatitis as the only dose-limiting toxicity; low overall hematologic toxicity, consistent with low circulating free-exatecan levels, supporting linker stabilityAntitumor activity
- Encouraging tolerability profile with stomatitis as the only dose-limiting toxicity; low overall hematologic toxicity, consistent with low circulating free-exatecan levels, supporting linker stability
- Antitumor activity observed across tumor types, including in post-enfortumab vedotin urothelial cancer; ORR of 33% (2/6) at the maximum tolerated dose of 3.6 mg/kg Q3W in non-urothelial tumors
- Initiating dose optimization with first patient planned in H1 2027, to further characterize safety and activity in post-EV urothelial cancer at upper dose levels and define a recommended Phase 2 dose and schedule
